Does Intensive Targeting Of Glycemia Really Matter For The Prevention Of Cardiovascular Disease?
Main Category: DiabetesAlso Included In: Cardiovascular / Cardiology; Endocrinology
Article Date: 18 Apr 2008 - 2:00 PDT
| Patient / Public: | ![]() |
3 (1 votes) |
| Healthcare Prof: | ![]() |
Recent reports have diabetes patients asking their doctors: "Is controlling my blood sugar level dangerous?" A panel of experts will consider the impact of glucose control through studies including ACCORD, ADVANCE, VADT, BARI-2D, Steno-2, ORIGIN, and NAVIGATOR and their meaning for the future of diabetes care. The symposium will take place between 3:00 and 4:45 PM on Friday, May 16, 2008, at the 17th Annual Meeting & Clinical Congress of the American Association of Clinical Endocrinologists (AACE), at the Walt Disney World Dolphin Resort in Orlando.
"There's a lot of information out there that's confusing for patients," AACE member and symposium chair Etie Moghissi, MD, FACP, FACE said. "As experts in diabetes care, it is the endocrinologists' job to make sure the patients have the facts."
The session will be divided into four sections, with an opportunity for the experts to answer audience questions. AACE member Dr. Faramarz Ismail-Beigi, an investigator in the ACCORD study and the Principal Investigator of the Ohio/Michigan Network of ACCORD, will discuss the implications of ACCORD, ADVANCE, VADT, and BARI-2D. AACE members George Grunberger, MD, FACE and Laurence Blonde, MD, FACE will discuss what has been learned from the STENO-2, ORIGIN, and NAVIGATOR trials.
"This symposium is an attempt to summarize what we hope to learn in the next few months from several on-going glycemia management trials focused on the prevention of cardiovascular disease," Dr. Ismail-Beigi said. "Discussing these studies will be beneficial for the medical community and the diabetes patients they treat."
This special symposium, "Clinical Trials Targeting Glycemia: What Do We Expect to Learn? ACCORD, ADVANCE, VADT & More" is part of the 17th Annual Meeting & Clinical Congress. Other sessions of interest at the meeting include, "Insulin Resistance and Atherosclerosis: The Missing Link," "Diabetes: A Cardiac Condition," and "Hypoglycemia: The Limiting Factor in the Glycemic Management of Diabetes."
Media Registration
American Association of Clinical Endocrinologists
Visit our diabetes section for the latest news on this subject.
MLA
16 Feb. 2012. <http://www.medicalnewstoday.com/releases/104535.php>
APA
http://www.medicalnewstoday.com/releases/104535.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.





